to describe the disease path and the very long-term outcome in a monocentric cohort of patients with Systemic Lupus Erythematosus (SLE).
Methods
SLE patients with a disease duration of at least 15 years from diagnosis were enrolled. The number of hospitalizations, the disease flares occurred over the disease course and the organ damage accumulation were evaluated at 1, 2, 3, 4, 5, 10 years from diagnosis and at last observation in 2019 as well. Disease state, ongoing therapies and quality of life measures were also assessed at last visit.
Results
126 Caucasian SLE patients were included in the analysis (95% female, median age 47.5 IQR 41–53, median disease duration 21 IQR19-26). At last visit, the majority of the patients (78.6%) was on LLDAS (remission included), 53.4% were on GC treatment and 35.7% on immunosuppressant. Furthermore, 53.2% had at least one organ damage. The majority of patients (66.7%) presented a relapsing-remitting course, for a total of 158 flares during the disease course (incidence rate: 0.79/patient-year); moreover, 84.9% of the cohort experienced at least one hospital admission, amounting to a total of 328 hospitalizations (incidence rate: 0.85/patient-year). The main reason for admission was disease activity, while the percentage of hospitalizations due to other causes has been growing over the 10 years of follow-up.
Conclusion
after a very long period of disease, most of the patients with SLE are in remission and are not taking GC therapy; however, the risk of incurring in disease flare remains a real problem.
Segura BT, Bernstein BS, McDonnell T, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology (Oxford) 2020; 59: 698.
2.
WadaYHasegawaHSaekiT, et al.
Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus. Clin Exp Nephrol2018;
22: 597–602.
3.
KasitanonNMagderLSPetriM.Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore)2006;
85: 147–156.
4.
SwaakAJNossentJCBronsveldW, et al.
Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis1989;
48: 447–454.
5.
WardMMPyunEStudenskiS.Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum1995;
38: 274–283.
6.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725–1710.
7.
GriffithsBMoscaMGordonC.Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol2005;
19: 685–708.
8.
GladmanDDGoldsmithCHUrowitzMB, et al.
The systemic lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol2000;
27: 373–376.
9.
BuyonJPPetriMAKimMY, et al.
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med2005;
142: 953–962.
10.
van VollenhovenRVoskuylABertsiasG, et al.
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis2017;
76: 554–561.
11.
FranklynKLauCSNavarraSV, et al.
Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis2016;
75: 1615–1621.
12.
BarrSGZonana-NacachAMagderLS, et al.
Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum1999;
42: 2682–2688.
13.
StollTGordonCSeifertB, et al.
Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol1997;
24: 1608–1614.
14.
GladmanDUrowitzMFortinP, et al.
Systemic lupus international collaborating clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic lupus international collaborating clinics group. J Rheumatol1996;
23: 1953–1955.
15.
YellenSBCellaDFWebsterK, et al.
Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage1997;
13: 63–74.
16.
JollyMGarrisCPMikolaitisRA, et al.
Development and validation of the lupus impact tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus. Arthritis Care Res (Hoboken)2014;
66: 1542–1550.
17.
YeeCSSuLToescuV, et al.
Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford)2015;
54: 836–843.
18.
SwaakAJvan den BrinkHGSmeenkRJ, et al.
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus2001;
10: 51–58.
19.
SwaakAJvan den BrinkHGSmeenkRJ, et al.
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford)1999;
38: 953–958.
20.
GyoriNGiannakouIChatzidionysiouK, et al.
Disease activity patterns over time in patients with SLE: analysis of the hopkins lupus cohort. Lupus Sci Med2017;
4: e000192.
21.
SteimanAJUrowitzMBIbanezD, et al.
Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol2014;
41: 1808–1816.
22.
DrenkardCVillaARGarcia-PadillaC, et al.
Remission of systematic lupus erythematosus. Medicine (Baltimore)1996;
75: 88–98.
23.
UrowitzMBGladmanDDIbanezD, et al.
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken)2012;
64: 132–137.
24.
ZhangJGonzalezLARosemanJM, et al.
Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus2010;
19: 727–733.
25.
Medina-QuinonesCVRamos-MerinoLRuiz-SadaP, et al.
Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken)2016;
68: 981–987.
26.
MinowaKAmanoHAndoS, et al.
Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: the JUDE study. Mod Rheumatol2017;
27: 72–76.
27.
RosaGPDOrtegaMFTeixeiraA, et al.
Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995–2015) from a single referral Centre in Catalonia. Lupus2019;
28: 1158–1166.
28.
EsmaeilzadehEKhodamoradiZNazariniaMA.One-decade study of distinct features, morbidity and mortality of systemic lupus erythematosus (an update on systemic lupus erythematosus in the Fars province of Iran). Lupus2019;
28: 1360–1367.
29.
MoscaMTaniCCarliL, et al.
Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol2011;
29: S126–S129.
30.
GladmanDDUrowitzMBRahmanP, et al.
Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol2003;
30: 1955–1959.
31.
Zonana-NacachABarrSGMagderLS, et al.
Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum2000;
43: 1801–1808.
32.
ApostolopoulosDMorandEF.It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford)2017;
56: i114–i122.
33.
van VollenhovenRFMoscaMBertsiasG, et al.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis2014;
73: 958–967.
34.
RivestCLewRAWelsingPM, et al.
Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol2000;
27: 680–684.
35.
RahmanPGladmanDDUrowitzMB, et al.
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus2001;
10: 93–96.
36.
ChambersSAAllenERahmanA, et al.
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford)2009;
48: 673–675.
37.
Becker-MerokANossentHC.Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol2006;
33: 1570–1577.
38.
TaraborelliMCavazzanaIMartinazziN, et al.
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus2017;
26: 1197–1204.
39.
ContiFCeccarelliFPerriconeC, et al.
The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus2016;
25: 719–726.
